Delineation of *TMPRSS2-ERG* Splice Variants in Prostate Cancer

Ying Hu,[1] Albert Dobi,[1,4] Taduru Sreenath,[1] Christopher Cook,[1] Atekelt Y. Tadase,[1] Lakshmi Ravindranath,[1] Jennifer Cullen,[1] Bungo Furusato,[1,2] Yongmei Chen,[1] Rajesh L. Thangapazham,[1] Ahmed Mohamed,[1] Chen Sun,[1] Isabell A. Sesterhenn,[2] David G. McLeod,[1,3,4] Gyorgy Petrovics,[1] and Shiv Srivastava[1,4]

Abstract

Purpose: The expression of the *ETS*-related gene (*ERG*) is low or undetectable in benign prostate epithelial cells. High prevalence of *ERG* overexpression in prostate cancer cells due to *TMPRSS2-ERG* fusions suggest for causal roles of ERG protein in the neoplastic process. *TMPRSS2-ERG* fusion junctions have been extensively studied in prostate cancer. However, virtually nothing is known about the nature of full-length transcripts and encoded proteins. This study focuses on qualitative and quantitative features of full-length *TMPRSS2-ERG* transcripts in prostate cancer.

Experimental Design: Full-length *TMPRSS2-ERG* transcripts were cloned and sequenced from a cDNA library generated from pooled RNA of six *TMPRSS2-ERG* fusion–positive prostate tumors. The encoded ERG proteins were analyzed in HEK293 cells. Copy numbers of *TMPRSS2-ERG* splice variants were determined by quantitative reverse transcription-PCR in laser capture microdissected prostate cancer cells.

Results: Two types of *TMPRSS2-ERG* cDNAs were identified: type I, which encodes full-length prototypical ERG protein (*ERG1, ERG2, ERG3*), and type II, encoding truncated ERG proteins lacking the ETS domain (*ERG8* and a new variant, *TEPC*). In microdissected prostate tumor cells from 122 patients, relative abundance of these variants was in the following order: *ERG8* > *TEPC* > *ERG 3* > *ERG1/2* with combined overexpression rate of 62.3% in prostate cancer. Increased ratio of type I over type II splice forms showed a trend of correlation with less favorable pathology and outcome.

Conclusions: Qualitative and quantitative features of specific *ERG* splice variants defined here promise to enhance the utility of *ERG* as a biomarker and therapeutic target in prostate cancer.

Molecular genetic evaluations of prostate cancer are defining mutational and expression alterations of critical oncogenes involved in disease onset and/or progression (reviewed in refs. 1–3). Discovery of prevalent chromosomal rearrangements/

translocations leading to the activation of ETS transcription factors (predominantly *ERG*) through the androgen receptor–regulated *TMPRSS2* gene promoter underscore the critical roles of *ERG*-encoded protein in prostate cancer (4–7). Because *ERG* represents the majority of *TMPRSS2-ETS* factor alterations described thus far (6, 7), we have focused on the expression and regulation of *TMPRSS2-ERG* in prostate cancer. Oncogenic functions of ETS factors, including ERG, have also been implicated in diverse cancers (8).

Structure and function of *ERG*-encoded proteins remain to be defined in prostate cancer. *ERG* consists of 17 exons spanning about 300 kb and generates at least nine alternate splice forms, seven of them coding for protein products of varying sizes (9). These *ERG* splice variants have been primarily described in nonprostate tissues. Despite the large body of data on the *TMPRSS2-ERG* fusion junctions in prostate cancer (reviewed in refs. 6, 7), virtually nothing is known about the full-length *TMPRSS2-ERG* transcripts in prostate cancer, including the existence and relative abundance of specific splice variants. In this context, it is important to note that the cancer-associated splice variants of numerous genes, e.g., *androgen receptor*, *fibroblast growth factor receptor*, *survivin*, and *MDM2*, have functional implications (10, 11). Thus, characterization of full-length *TMPRSS2-ERG* transcripts is essential to better understand *ERG* function(s) in prostate cancer and to further enhance its utility as biomarker and therapeutic target.

Fig. 1. Expression of *TMPRSS2-ERG* fusions in prostate cancer specimens. *A,* evaluation of the prevalence of *TMPRSS2-ERG* fusion A transcript junctions in prostate cancer patients (*N* = 122): Tumor and matching benign cells were assayed for *TMPRSS2-ERG*, *TMPRSS2-ETV1*, and *TMPRSS2-ETV4* fusion transcript junctions by quantitative reverse transcription-PCR. The schematic representation depicts the distribution of the various fusions in the patient specimens. The pie chart summarizes the *TMPRSS2-ERG* fusion junction types in the 122 tumor specimens. inset, *TMPRSS2-ERG* fusion A (*T1-E8*), B (*T1-E3*), and C (*T1-E9*) detected in this study (exon numbering is according to ref. 9). *B,* schematic representation of the experimental strategy and workflow of quantitative gene expression analysis in prostate tumor specimens.

In this study, we have cloned and sequenced full-length cDNAs from *TMPRSS2-ERG* fusion–positive prostate tumors, and from the VCaP cell line. We have identified two types of *TMPRSS2-ERG* cDNAs, one (type I) encoding full-length prototypical ERG protein (*ERG1*, *ERG2*, *ERG3*) and the other (type II) encoding a shorter version lacking the ETS domain (*ERG8* and a new variant, *TEPC*). We have further quantified and validated the expression of these *ERG* splice forms in a large cohort of prostate cancer specimens. The *ERG* exons at the *TMPRSS2-ERG* fusion junction have been the subject of a number of studies (fusion junction variants; refs. 5–7, 12–19). However, these exons are present in all *ERG* splice forms and do not identify specific splice variants. In recent *in vivo* models assessing the role of ERG in prostate cancer, only a type I splice

variant, specifically NH$_2$-terminally truncated *ERG3*, was tested (20, 21). Intriguingly, the data presented here shows a more abundant expression of type II splice variants in prostate cancer cells. Our new findings on *ERG* splice variants in prostate cancer have promise in improving the understanding of *ERG* functions and its therapeutic targeting in prostate cancer, as well as in enhancing the detection of *ERG* alterations in clinical specimens.

Materials and Methods

Tissue specimens, laser capture microdissection, and quantitative gene expression analysis. The prostate tissue specimens used in this study

were obtained from radical prostatectomy procedures under an Institutional Review Board–approved protocol at Walter Reed Army Medical Center. Laser capture microdissection (LCM) of tumor and benign epithelial cells from optimum cutting temperature–embedded frozen tissues obtained from the radical prostatectomy specimens, RNA isolation from the LCM samples, and real-time quantitative reverse transcription-PCR (TaqMan) were essentially done as described previously (4, 22). The differentiation status of microdissected cells was recorded independently from the overall pathologic Gleason grade of the prostate, which was determined from whole-mounted, formalin-fixed, paraffin-embedded prostate specimens of each patient. The small amounts of tissue specimens (~ 5 mm^3) were obtained for optimum cutting temperature embedding from radical prostatectomy specimen before whole-mount prostate processing. Selection of specimens for LCM was primarily driven by the presence of sufficient amount of tumor cells for the LCM. The predominant tumor cell type (by differentiation) present in a frozen section was microdissected. Most of the time, but not always, the predominant differentiation grade in frozen tissue section represented the prevalent differentiation grade of the tumor cells in the prostate. Overall, 88.4% of LCM samples were collected from the primary Gleason pattern of the index tumor. Because of this, we have compared the quantitative gene expression of *TMPRSS2-ERG* splice variants to the differentiation grade of the microdissected cells, as well as to the overall differentiation grade of the of tumor cells in the prostate. Overall conclusions were similar by two-way comparisons but an increased statistically significant relationship was noted when the gene expression ratios of ERG I/II in LCM-

RNAs was correlated with the differentiation grade of the LCM-dissected cells. TaqMan primers and probes are listed in the Supplementary data.

Detection of the *TMPRSS2-ERG* and *TMPRSS2-ETV* fusion transcripts was done essentially as described (5). The different *TMPRSS2-ERG* fusion junction types (A, B, and C) are described in Fig. 1A in a schematic diagram. All three fusion types have been previously described (5, 19). The expression of *GAPDH* was simultaneously analyzed as endogenous control, and the target gene expression in each sample (in duplicates) was normalized to *GAPDH*. RNA samples without reverse transcription were included as the negative control in each assay.

Generation and screening of cDNA library from prostate tumors. For the generation of the cDNA library, frozen tumor tissues from index tumors of six patients were selected based on available tissue size (over 30 mg), highest tumor cell content (over 70%), and the presence of *TMPRSS2-ERG* fusion transcripts by reverse transcription-PCR. Polyadenylated RNA was isolated from the optimum cutting temperature–embedded frozen tumor tissues. A cDNA library was generated from the pooled RNA (Lofstrand Laboratories) and cloned into the *Xho*I-*Eco*RI sites of lambdaZAP Express vector (Stratagene). Screening of the expression library was carried out according to the protocol described by the manufacturer (Stratagene). The primary library of about 400,000 plaques were screened by *ERG2* probe (NM_004449; cDNA obtained from Dr. Dennis Watson, Medical University of South Carolina, Charleston, SC) and found 84 hybridized with different intensities. The positive plaques were further screened for the presence of *TMPRSS2* fusions by fusion-specific PCR (5). A total of 12 plaques showed


Fig. 2. *ERG* splice forms in prostate tumors and their expression in the VCaP prostate cancer cell line. *A,* schematic representation of full-length type I and type II *ERG* transcripts expressed in prostate cancer cells with *TMPRSS2-ERG* fusion. Numbered boxes, *ERG* exons (9); boxes with * and **, unique regions of *TEPC* and *ERG8*, respectively. Solid lines above the exons, TaqMan primers and probes used for the detection of the *ERG* splice variants. *B,* type I transcripts code for both transactivation (*SAM Pointed*) and DNA-binding (*ETS*) domains. In contrast, type II variants lack the coding sequence for the DNA-binding domain. The relative positions coding for the two major functional domains of ERG protein are shown in type I and type II splice variants. *C,* columns, copy numbers of the *ERG* splice forms in VCaP cells determined by TaqMan quantitative reverse transcription-PCR. The median of three experiments using triplicates are shown. *D,* protein products expressed from *TMPRSS2-ERG2*, *TMPRSS2-ERG3*, and *TMPRSS2-ERG8* clones transiently transfected into HEK293 cells are shown by Western blot analysis. Anti-Flag antibody was used for the detection of Flag-tagged ERG8 protein.

Fig. 3. Quantitative expression of *ERG* splice variants in prostate cancer patients. *A,* quantitative expression of *ERG* splice forms *ERG8,TEPC, ERG3*, and *ERG1&2* (*columns with different colors*) were determined in microdissected tumor cells of prostate cancer patients (*N* = 122). The graph depicts relative expression levels (copy number/ng total RNA, normalized to *GAPDH*) in patients with (*top, n* = 66) and with no detectable (*bottom, n* = 56) *TMPRSS2-ERG* fusion A transcript junction. Due to wide dynamic range of copy numbers, the values above 5,000 are not shown here (the range of expression for each splice variant is depicted in *B*). In the pie chart, the percentage of prostate cancer patients are represented either with higher (∼77%) or with lower (∼23%) expression level of type II than type I *ERG* transcripts. *B,* relative abundance of various *ERG* splice forms (*ERG8,TEPC, ERG3*, and *ERG1&2*) is depicted by box plots representing the copy numbers determined in 76 prostate cancer patients overexpressing *ERG*. *C,* pie charts illustrate the distribution of prostate cancer patients with various expression levels (copy number/ng total RNA) of *ERG8,TEPC, ERG3*, and *ERG1&2* splice forms in prostate cancer cells.

amplification. Detailed cDNA sequence analysis revealed the presence of two types of *TMPRSS2-ERG* fusion transcripts. Within the positively identified plaques, three represented type I (with both SAM domain and DNA-binding ETS domain) and five type II (without ETS domain). Fusion-positive type I– and type II–containing phages were amplified with T3 and T7 primers, subcloned into TOPO vector (Invitrogen), and verified by DNA sequencing.

Cell culture and Western blot. The prostate cancer cell line VCaP, which has type A *TMPRSS2-ERG* fusion (5), and human embryonic kidney HEK 293 cells were obtained from the American Type Culture Collection. Cells were cultured according to the provider's instructions[5] and harvested upon confluence of 70%. RNA was isolated by RNAzol B method (Tel-Test, Inc.). *TMPRSS2-ERG2*, *TMPRSS2-ERG3*, and *TMPRSS2-ERG8* (Flag-tagged) constructs were cloned from prostate cancer cDNA library into pIRES-EGFP plasmid vector (Clontech) and were verified by DNA sequencing. HEK293 cells transfected with the constructs were lysed in M-PER mammalian protein extraction reagent (Pierce) supplemented with protease and phosphatase inhibitor cocktails (Sigma). ERG2 and ERG3 proteins were detected by Western blot (NuPAGE Bis-Tris gel, Invitrogen) using immunoaffinity-purified anti-ERG peptide polyclonal antibody prepared in our laboratory (DFHGI AQALQ PHPPE SSLYK YPSDL PYMGS YHAHP QKMNF VAPHP PAL). The tagged ERG8 protein was detected by Flag-tag antibody (Sigma).

Statistical analyses of clinical and gene expression data. Measures of central tendency (median) and dispersion (range) are used to describe continuously measured patient characteristics, whereas frequencies and

percentages are used to describe categorical patient characteristics. χ^2 and Fisher's exact tests were conducted to compare *TMPRSS2-ERG* splice variant transcript expression across patient clinical and demographic characteristics. *P* values <0.05 are considered statistically significant.

Results

Quantitative analysis of TMPRSS2-ERG expression in prostate tumors. Quantitative analyses of the transcript levels of various *TMPRSS2-ETS* fusion genes were done in LCM matched benign and tumor epithelium of prostate cancer specimens (122 patients; 244 specimens; Fig. 1A). The demographic, clinical, and pathologic variables of the patient cohort are summarized in Supplementary Table S1. The workflow of LCM and quantitative reverse transcription-PCR analysis is summarized in Fig. 1B. The most frequently observed *TMPRSS2-ERG* fusion transcript junctions (6, 7) were detected in 57% of the patients, and among these 95% expressed *TMPRSS2-ERG* fusion type A (Fig. 1A). Fusions with other ETS family members, such as *TMPRSS2-ETV1* or *TMPRSS2-ETV4*, were not detected in this cohort. No fusions were detected in matched benign prostate epithelial cells dissected from the same prostate.

Identification of full-length TMPRSS2-ERG transcripts in prostate tumors. To investigate the nature of *TMPRSS2-ERG*–encoded proteins in prostate cancer, a cDNA library was generated from RNA pooled from six prostate tumors with

---

[5] http://www.atcc.org

TMPRSS2-ERG fusion. Screening of the library (see flow chart in Supplementary Fig. S1) by both *ERG* and *TMPRSS2* probes resulted in the identification of the following *ERG* splice variants: *ERG1* (M21535), *ERG2* (NM004449), *ERG3* (NM182918), *ERG8* (AY204742), and *TEPC*, a novel splice variant (EU432099; Fig. 2A). *ERG1*, *ERG2*, and *ERG3* contain both SAM (pointed) and ETS (DNA-binding) domain (type I); however, *ERG8* and *TEPC* lack the ETS domain (type II; Fig. 2B). Among the positively identified cDNA library clones, 30% were type I and 70% were type II. Both types of *ERG* transcripts are expressed in VCaP cells, a human prostate cancer cell line derived from vertebral metastasis that harbors *TMPRSS2-ERG* fusion, with the type II transcripts being more abundant (Fig. 2C).

HEK293 cells were transiently transfected with the *TMPRSS2-ERG2*, *TMPRSS2-ERG3*, and *TMPRSS2-ERG8* constructs and the expressed ERG proteins were detected by Western blot showing the expected molecular weight of type I and type II proteins (Fig. 2D). For the detection of type I splice forms (ERG2 and ERG3), an anti-peptide polyclonal ERG antibody was used, which was developed in our laboratory. ERG8, a type II splice form, was Flag-tagged and detected by anti-Flag antibody, because ERG8 lacks part of our ERG peptide epitope.

Relative abundance of type II ERG splice forms in tumor cells of prostate cancer patients. Quantitative expression of the *ERG* splice variants were determined in microdissected tumor cells of 122 prostate cancer patients: 66 with *TMPRSS2-ERG* fusion A transcript junction and 56 with no detectable fusion A

transcript (Fig. 3A). At least two or more *ERG* splice variants were detectable in all *TMPRSS2-ERG* fusion A – positive prostate cancer patients. *ERG8* and *TEPC* represented the most abundant *ERG* splice forms analyzed (Fig. 3B) and were detected in 65 of 66 *TMPRSS2-ERG* fusion A expression – positive patients (Fig. 3A). Expression of at least two of the *ERG* splice forms was detected in 10 of 56 fusion A expression – negative cases. Three of these tumors were positive for *TMPRSS2-ERG* fusion types B or C. It is likely that other such tumors may harbor other *TMPRSS2-ERG* fusion junctions. Thus, quantitative analysis of *ERG* splice variants, especially *ERG8* and *TEPC*, provide a reliable surrogate for *TMPRSS2-ERG* fusion in prostate cancer, and in addition it detects *ERG* overexpression even if the fusion junction type is unknown. The order of median abundance (copies/ng total RNA) of *ERG* splice forms in prostate cancer cells of 76 patients with detectable *ERG* expression was *ERG8* (~ 3,200) > *TEPC* (~ 1,800) > *ERG3* (~ 1,500)> *ERG1&2* (~ 800; Fig. 3B). Overall, the type II splice variants (with no ETS domain) were present in higher copy numbers in prostate cancer cells than the type I splice forms (Fig. 3B and C), and 77% of *ERG*-positive prostate cancer patients tested have more copies of type II than type I splice forms (Fig. 3A). We conclude that quantitative detection of *ERG* splice variants, especially *ERG8* and *TEPC*, may provide increased sensitivity in assessing overall frequency of *TMPRSS2-ERG* fusions in prostate cancer cells.

Expression of ERG splice forms in relation to clinicopathologic variables of prostate cancer patients. In comparison with

Table 1. Correlation of *ERG* splice variant expression and type I/type II ratio with clinicopathologic characteristics

Clinicopathologic characteristics	*ERG* splice variant expression			Type I/ type II ratio		
	No (46)	Yes (76)	P*	n (76)	Median	P †
Race			0.0345			0.1142
Caucasian	29 (33%)	59 (67%)		59	0.51	
African American	15 (56%)	12 (44%)		12	0.33	
Family history			0.6312			0.3259
No	28 (38%)	45 (62%)		45	0.52	
Yes	10 (33%)	20 (67%)		20	0.51	
Pathologic T stage			0.5318			0.2541
pT_2	14 (36%)	25 (64%)		25	0.44	
pT_3	29 (42%)	40 (58%)		40	0.51	
Pathologic Gleason sum			0.0023			0.0323
2-6	9 (24%)	29 (76%)		29	0.35	
7	20 (36%)	36 (64%)		36	0.46	
8-10	14 (70%)	6 (30%)		6	0.70	
LCM differentiation			0.0058			0.0067
Well	31 (32%)	66 (68%)		65	0.45	
Poorly	15 (62%)	9 (38%)		9	0.76	
Margin status			0.9436			0.0032
Negative	28 (38%)	45 (62%)		45	0.39	
Positive	16 (39%)	25 (61%)		25	0.57	
PSA recurrence			0.7312			0.0456
No	33 (37%)	56 (63%)		56	0.42	
Yes	11 (41%)	16 (59%)		16	0.61	

NOTE: *ERG* splice variant expression (*N* = 122): In comparison with patients with no detectable expression of *ERG* in their prostate cancer cells (*n* = 46), the *ERG*-positive patient cohort (*n* = 76) has a decreased proportion of patients with high Gleason grade, poor prostate cancer cell differentiation, and African American ethnicity. Type I/type II ratio (*n* = 76): The ratio of *ERG* type I/type II splice variants in prostate cancer cells is increased in patients with poor tumor cell differentiation and with prostate-specific antigen recurrence.
Abbreviation: PSA, prostate-specific antigen.
*Two-sided test, *P* < 0.05 was considered statistically significant.
† One-sided test, *P* < 0.05 was considered statistically significant.

prostate cancer patients with no detectable *ERG* expression (n = 46), the *ERG* expression–positive patient cohort (n = 76) has a smaller proportion of patients with high pathologic Gleason grade (8–10), poor prostate cancer cell differentiation, or African American ethnicity (Table 1). The levels of type I or type II *ERG* splice forms in the cohort of prostate cancer patients with *ERG* expression (n = 76) did not show significant correlations with clinicopathologic variables. However, there was a trend of correlation of higher copy number ratio of type I over type II splice forms with poor differentiation of prostate cancer cells, higher pathologic Gleason sum, positive margin, and biochemical recurrence (Table 1).

Discussion

ERG overexpression as a result of *TMPRSS2-ERG* fusion represents a highly prevalent oncogenic alteration in prostate cancer. Remarkable progress has been made in just over 2 years in establishing the diagnostic and prognostic features of *TMPRSS2-ERG* fusion in prostate cancer (6, 7). Despite the large body of data on the *TMPRSS2-ERG* fusion junctions, virtually nothing is known about the full-length *TMPRSS2-ERG* transcripts, including the existence and relative abundance of specific splice variants in human prostate tumors. However, splice variants of numerous genes, e.g., *androgen receptor*, *fibroblast growth factor receptor*, *survivin*, and *MDM2*, are known to play critical roles in various human cancers (10, 11).

This study establishes the nature of full-length *TMPRSS2-ERG* transcripts and encoded proteins in prostate cancer cells. In addition to expected full-length *TMPRSS2-ERG* transcripts, we have identified relatively abundant *ERG* splice forms with unique 3′ sequences that lack a conserved region coding for the DNA binding ETS domain. Parallel quantitative analyses of *ERG* splice variants in precisely microdissected cells from well-defined histologic features of the tumor provided accurate data with respect to the presence, abundance, and distribution of various *ERG* splice forms in prostate cancer in relation with clinicopathologic status.

Monitoring the expression of *ERG* splice variants, we detected more prostate cancer cases than by monitoring the fusion transcript junctions, likely because unknown or undetected fusions are present in a subset of cases. Furthermore, the number of various fusion junctions in prostate cancer is far more than the number of *ERG* splice variants.

Recent reports revealed that specific junction types of *TMPRSS2-ERG* fusion transcripts, genomic deletions, or the presence of *TMPRSS2-ERG* fusion are associated with poor prognosis (reviewed in refs. 6, 7). However, others reported that fusion-positive tumors were associated with lower Gleason grade and/or better disease outcome (12). In this study, we found that compared with patients with no detectable

expression of *ERG* in their prostate cancer cells, the *ERG* expression–positive patient cohort has a decreased proportion of patients with high Gleason grade, poor prostate cancer cell differentiation, and African American ethnicity (N = 122). This is in agreement with our previous study on *ERG* expression in prostate cancer (4). Lower or no *ERG* expression in a subset of aggressive tumors with *TMPRSS2-ERG* fusion may reflect attenuation of androgen signaling pathway during prostate cancer progression (23). The levels of type I or type II *ERG* splice forms did not show significant correlations with clinicopathologic variables. It will be useful to combine multiple approaches, including quantitative assessment of *TMPRSS2-ERG* expression levels, evaluation of genomic rearrangements, and different types of transcripts in multicenter cohort to confirm prognostic values of qualitative and quantitative aspects of *ERG* alterations in prostate cancer.

The diversity of *TMPRSS2-ERG* fusion transcripts has recently been emphasized focusing on the fusion junction region of the transcripts (13, 14) and by using exon arrays (15) that did not allow for the discovery of the type II splice variants described here. Our results highlight the importance of understanding the expression and distribution of full-length splice forms of *ERG*, including variants with no DNA binding domain, in the tumor cells. Our data show a trend of correlation of relatively more type I over type II splice forms, with less favorable pathology and outcome that need to be confirmed in a larger patient cohort. The heterogeneity of *TMPRSS2-ERG* rearrangements in multifocal prostate cancer reported by our group and others (18, 19) further adds to the complexity of understanding the roles of *ERG* in prostate cancer.

In conclusion, this study establishes two major types of full-length transcripts from the *TMPRSS2-ERG* locus in prostate cancer. Further, we establish the protein products translated from type I and type II transcripts. The presence of these specific *ERG* splice forms, especially the more abundant type II splice forms, may provide new opportunities in as prostate cancer biomarker. Finally, overall status of the type I and II forms in prostate cancer cells, such as the ratio of their expression levels, has potential to enhance our understanding of the biology of prostate tumors with *TMPRSS2-ERG* fusion.

References

1. De Marzo AM, Platz EA, Sutcliffe S, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7:256–69.
2. Richter E, Srivastava S, Dobi A. Androgen receptor and prostate cancer. Prostate Cancer Prostatic Dis 2007;10:114–8.
3. Kallioniemi O. Functional genomics and transcriptomics of prostate cancer: promises and limitations. BJU Int 2005;96 Suppl 2:10–5.
4. Petrovics G, Liu A, Shaheduzzaman S, et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 2005;24: 3847–52.
5. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644–8.
6. Turner DP, Watson DK. ETS transcription factors: oncogenes and tumor suppressor genes as therapeutic targets for prostate cancer. Expert Rev Anticancer Ther 2008;8:33–42.
7. Demichelis F, Rubin MA. TMPRSS2-ETS fusion prostate cancer: biological and clinical implications. J Clin Pathol 2007;60:1185–6.
8. Seth A, Watson DK. ETS transcription factors and their emerging roles in human cancer. Eur J Cancer 2005;41:2462–78.
9. Owczarek CM, Portbury KJ, Hardy MP, et al. Detailed

mapping of the ERG-ETS2 interval of human chromosome 21 and comparison with the region of conserved synteny on mouse chromosome 16. Gene 2004;324: 65–77.

10. Venables JP. Unbalanced alternative splicing and its significance in cancer. Bioessays 2006;28:378–86.

11. Steinman HA, Burstein E, Lengner C, et al. An alternative splice form of Mdm2 induces p53-independent cell growth and tumorigenesis. J Biol Chem 2004; 279:4877–86.

12. Tu JJ, Rohan S, Kao J, et al. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Mod Pathol 2007;20:921–28.

13. Clark J, Merson S, Jhavar S, et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene 2007;26:2667–73.

14. Liu W, Ewing CM, Chang BL, et al. Multiple genomic alterations on 21q22 predict various TMPRSS2/ERG fusion transcripts in human prostate cancers. Genes Chromosomes Cancer 2007;46:972–80.

15. Jhavar S, Reid A, Clark J, et al. Detection of TMPRSS2-ERG translocations in human prostate cancer by expression profiling using GeneChip Human Exon 1.0 ST arrays. J Mol Diagn 2008;10:50–7.

16. Rajput AB, Miller MA, De Luca A, et al. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol 2007;60:1238–43.

17. Wang J, Cai Y, Ren C, Ittmann M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 2006;66:8347–51.

18. Mehra R, Han B, Tomlins SA, et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res 2007;67:7991–5.

19. Furusato B, Gao CL, Ravindranath L, et al. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod Pathol 2008;21:67–75.

20. Klezovitch O, Risk M, Coleman I, et al. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci U S A 2008;105:2105–10.

21. Tomlins SA, Laxman B, Varambally S, et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008;10:177–88.

22. Petrovics G, Zhang W, Makarem M, et al. Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. Oncogene 2004; 23:605–11.

23. Sterbis JR, Gao C, Furusato B, et al. Higher expression of the androgen-regulated gene PSA/HK3 mRNA in prostate cancer tissues predicts biochemical recurrence-free survival. Clin Cancer Res 2008;14: 758–63.

Clinical Cancer Research

Delineation of *TMPRSS2-ERG* Splice Variants in Prostate Cancer

Ying Hu, Albert Dobi, Taduru Sreenath, et al.

Clin Cancer Res 2008;14:4719-4725.

Updated version	Access the most recent version of this article at: http://clincancerres.aacrjournals.org/content/14/15/4719
Supplementary Material	Access the most recent supplemental material at: http://clincancerres.aacrjournals.org/content/suppl/2008/08/25/14.15.4719.DC1

Cited articles	This article cites 23 articles, 8 of which you can access for free at: http://clincancerres.aacrjournals.org/content/14/15/4719.full#ref-list-1
Citing articles	This article has been cited by 9 HighWire-hosted articles. Access the articles at: http://clincancerres.aacrjournals.org/content/14/15/4719.full#related-urls

E-mail alerts	Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
Permissions	To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/14/15/4719. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.